Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
Popik Piotr, Hogendorf Adam, Bugno Ryszard, Khoo Shaun Yon-Seng, Zajdel Pawel, Malikowska-Racia Natalia, Nikiforuk Agnieszka, Golebiowska Joanna
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (56)
- Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. 2021-01-01 · Expand citations
- Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. 2020-02-28 · Expand citations
- Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. 2019-08-01 · Expand citations
- Rapid-Acting Antidepressants. 2018-01-01 · Expand citations
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016-07-01 · Expand citations
- Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom” 2003-06-01 · Expand citations
- 10.1001/archpsyc.1994.03950030035004
- 10.1001/archpsyc.63.8.856
- 10.1002/0471264180.os080.26
- 10.1007/bf00433008
- 10.1007/pl00005481
- 10.1007/s00213-002-1154-7
- 10.1007/s00213-009-1500-0
- 10.1007/s00213-010-1834-7
- 10.1007/s00213-011-2277-5
- 10.1007/s00213-016-4389-4
- 10.1007/s002280100353
- 10.1007/s00406-020-01110-5
- 10.1016/0006-8993(84)91326-x
- 10.1016/0014-2999(90)90204-j
- 10.1016/0031-9384(92)90170-7
- 10.1016/j.biopsych.2006.11.017
- 10.1016/j.biopsych.2010.03.004
- 10.1016/j.euroneuro.2013.03.002
- 10.1016/j.euroneuro.2014.04.007
- 10.1016/j.euroneuro.2020.09.004
- 10.1016/j.jad.2014.12.057
- 10.1016/j.neuropharm.2016.03.038
- 10.1016/j.pbb.2006.07.019
- 10.1016/j.pbb.2020.173011
- 10.1016/j.tips.2009.09.002
- 10.1016/s0006-3223(99)00230-9
- 10.1016/s0166-4115(96)80059-8
- 10.1016/s0166-4115(97)80055-6
- 10.1016/s0166-4115(97)80056-8
- 10.1016/s0924-977x(96)00042-9
- 10.1016/s2215-0366(19)30292-5
- 10.1021/acs.oprd.9b00436
- 10.1037/0097-7403.7.1.18
- 10.1037/0097-7403.9.2.171
- 10.1037/a0024722
- 10.1038/s41380-021-01093-2
- 10.1038/s41467-020-20190-4
- 10.1057/978-1-137-40883-9_10
- 10.1093/schbul/sbx050
- 10.1097/00000542-198204000-00011
- 10.1097/00008877-199708000-00003
- 10.1097/01.fbp.0000189810.69425.89
- 10.1097/fbp.0b013e328334707a
- 10.1177/0269881106065859
- 10.1177/0956797611435817
- 10.1192/bjp.bp.105.015263
- 10.1371/journal.pone.0115374
- 10.7554/elife.11386